Q301--NEW – STX Specialized Molecular Residual Disease Testing

This notice announces the Department of Veterans Affairs’ intent to award an IDIQ, firm‑fixed‑price, sole‑source contract to Natera, Inc. for proprietary molecular genetic reference testing (Signatera and Prospera) used in transplant patient monitoring and cancer residual disease assessment. The work will be performed at VA facilities in Texas (VISN 17) under five future ordering periods, with the government retaining discretion to later open competition. • Sole‑source award to Natera, Inc. – only vendor possessing the required proprietary assays. • Services include Signatera Residual Disease Test (CPT 81479, 81455) – 35 units; Prospera transplant assessment test (CPT 81479) – 25 units. • IDIQ structure: up to five ordering periods; exact dates to be determined after award. • Capability statements (not quotes) were requested by November 2 2026.